0001438934-24-000509.txt : 20240821 0001438934-24-000509.hdr.sgml : 20240821 20240821171813 ACCESSION NUMBER: 0001438934-24-000509 CONFORMED SUBMISSION TYPE: N-PX PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240821 EFFECTIVENESS DATE: 20240821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MPM BioImpact LLC CENTRAL INDEX KEY: 0001687078 ORGANIZATION NAME: IRS NUMBER: 364818254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: N-PX SEC ACT: 1934 Act SEC FILE NUMBER: 028-20107 FILM NUMBER: 241229460 BUSINESS ADDRESS: STREET 1: 399 BOYLSTON STREET, SUITE 1100 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 399 BOYLSTON STREET, SUITE 1100 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: BioImpact Capital LLC DATE OF NAME CHANGE: 20210831 FORMER COMPANY: FORMER CONFORMED NAME: MPM Oncology Impact Management LP DATE OF NAME CHANGE: 20161007 N-PX 1 primary_doc.xml N-PX IM LIVE 0001687078 XXXXXXXX 06/30/2024 YEAR 2024 MPM BioImpact LLC 6174259203

399 Boylston Street Suite 1100 Boston MA 02116

INSTITUTIONAL MANAGER VOTING REPORT N 028-20107 309865 801-119133 Y null 1 1 028-20107 309865 801-119133 MPM BIOIMPACT LLC Brendan Furey Brendan Furey Brendan Furey Chief Compliance Officer 08/20/2024 PROXY VOTING RECORD 2 BRDQRW_0001687078_2024.xml VOTE TABLE 89BIO, INC.282559103US282559103305/29/2024Approval of, on an advisory basis, the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER7491210FOR749121FOR1 89BIO, INC.282559103US282559103305/29/2024Advisory vote on the frequency of future advisory votes on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER74912101 YEAR749121FOR1 AKERO THERAPEUTICS, INC00973Y108US00973Y108206/07/2024To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER2577730FOR257773FOR1 ALX ONCOLOGY HOLDINGS INC00166B105US00166B105206/12/2024Advisory vote to approve named executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER5886380FOR588638FOR1 AMICUS THERAPEUTICS, INC.03152W109US03152W109906/06/2024Approval, on a advisory basis, the Company's executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER5566690FOR556669FOR1 AXSOME THERAPEUTICS, INC.05464T104US05464T104306/07/2024To approve, by non-binding advisory vote, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER883610FOR88361FOR1 CALLIDITAS THERAPEUTICS ABW2R50Z137SE001044158406/17/2024APPROVE REMUNERATION REPORTSECTION 14A SAY-ON-PAY VOTESISSUER483290FOR48329FOR1 CARTESIAN THERAPEUTICS, INC.816212302US816212302506/14/2024To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation."SECTION 14A SAY-ON-PAY VOTESISSUER1687450FOR168745FOR1 CHINOOK THERAPEUTICS, INC.16961L106US16961L106108/02/2023To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to Company's named executive officers in connection with the MergerSECTION 14A SAY-ON-PAY VOTESISSUER7559970FOR755997FOR1 CRINETICS PHARMACEUTICALS INC.22663K107US22663K107906/07/2024To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange CommissionSECTION 14A SAY-ON-PAY VOTESISSUER3721000FOR372100FOR1 GERON CORPORATION374163103US374163103605/09/2024To approve, on an advisory basis, the compensation of the company's named executive officers, as disclosed in the company's proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER26897860FOR2689786FOR1 INSMED INCORPORATED457669307US457669307505/13/2024An advisory vote on the 2023 compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER4073000FOR407300FOR1 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/12/2024Approve, on a non-binding advisory basis, the compensation of the named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER593660FOR59366FOR1 IOVANCE BIOTHERAPEUTICS, INC.462260100US462260100706/11/2024To approve, by non-binding advisory vote, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER8632830FOR863283FOR1 IVERIC BIO, INC.46583P102US46583P102107/06/2023To approve, by non-binding, advisory vote, compensation that may be paid or become payable by IVERIC to its named executive officers in connection with the MergerSECTION 14A SAY-ON-PAY VOTESISSUER4956910FOR495691FOR1 KALVISTA PHARMACEUTICALS, INC.483497103US483497103209/26/2023Approve, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in this proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER5737110FOR573711FOR1 KARUNA THERAPEUTICS, INC.48576A100US48576A100703/12/2024To approve, on an advisory, non-binding basis, certain compensation that will or may be paid by Karuna to its named executive officers that is based on or otherwise related to the merger of Merger sub with and into Karuna pursuant to the merger agreement.SECTION 14A SAY-ON-PAY VOTESISSUER403380FOR40338FOR1 MADRIGAL PHARMACEUTICALS INC.558868105US558868105706/25/2024Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER431680FOR43168FOR1 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/05/2024Approval of, on an advisory basis, the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER2292200FOR229220FOR1 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/05/2024Non-binding advisory vote on the frequency of future advisory votes on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER22922001 YEAR229220FOR1 MORPHIC HOLDING, INC.61775R105US61775R105906/04/2024To approve, on a non-binding advisory basis, the compensation paid to the Company's Named Executive OfficersSECTION 14A SAY-ON-PAY VOTESISSUER2518920FOR251892FOR1 NATERA, INC.632307104US632307104206/12/2024To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER1334940FOR133494FOR1 OLEMA PHARMACEUTICALS, INC.68062P106US68062P106606/13/2024Approval, on an advisory basis, of the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER3896810FOR389681FOR1 OSE IMMUNOTHERAPEUTICS SAF6913C100FR001212717306/19/2024APPROVAL OF FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS COMPRISING THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND PAID DURING THE CURRENT FINANCIAL YEAR OR AWARDED IN RESPECT OF THE PREVIOUS ONE, TO THE CHAIRMAN OF THE BOARD OF DIRECTORSSECTION 14A SAY-ON-PAY VOTESISSUER2549770FOR254977FOR1 OSE IMMUNOTHERAPEUTICS SAF6913C100FR001212717306/19/2024APPROVAL OF FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS COMPRISING THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND PAID DURING THE CURRENT FINANCIAL YEAR OR AWARDED IN RESPECT OF THE PREVIOUS ONE, TO THE CHAIRMAN OF THE MANAGING DIRECTORSECTION 14A SAY-ON-PAY VOTESISSUER2549770FOR254977FOR1 REATA PHARMACEUTICALS, INC.75615P103US75615P103009/21/2023To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Merger contemplated by the Merger AgreementSECTION 14A SAY-ON-PAY VOTESISSUER1758500FOR175850FOR1 REGENXBIO INC.75901B107US75901B107005/31/2024To approve, on an advisory basis, the compensation paid to the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER375230FOR37523FOR1 REVOLUTION MEDICINES, INC.76155X100US76155X100006/20/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (''Say-on-Pay'')SECTION 14A SAY-ON-PAY VOTESISSUER822010FOR82201FOR1 SUTRO BIOPHARMA, INC.869367102US869367102106/06/2024To approve, on a non-binding, advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER13021210FOR1302121FOR1 ULTRAGENYX PHARMACEUTICAL INC.90400D108US90400D108106/18/2024Advisory (non-binding) vote to approve the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER2204910FOR220491FOR1 VIKING THERAPEUTICS INC92686J106US92686J106005/21/2024To approve, on an advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER1145010FOR114501FOR1 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/17/2024To approve, on an advisory basis, the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER5104220FOR510422FOR1 XERIS BIOPHARMA HOLDINGS, INC.98422E103US98422E103806/05/2024To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER322593501 YEAR3225935FOR1 XERIS BIOPHARMA HOLDINGS, INC.98422E103US98422E103806/05/2024To approve, on a non-binding advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER32259350FOR3225935FOR1 ZENTALIS PHARMACEUTICALS, INC.98943L107US98943L107006/21/2024To approve, on an advisory (non-binding) basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER4721110FOR472111FOR1 89BIO, INC.282559103US282559103305/29/2024Approval of, on an advisory basis, the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER2318570FOR231857FOR1 89BIO, INC.282559103US282559103305/29/2024Advisory vote on the frequency of future advisory votes on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER23185701 YEAR231857FOR1 AKERO THERAPEUTICS, INC00973Y108US00973Y108206/07/2024To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER797820FOR79782FOR1 ALX ONCOLOGY HOLDINGS INC00166B105US00166B105206/12/2024Advisory vote to approve named executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER1821870FOR182187FOR1 AMICUS THERAPEUTICS, INC.03152W109US03152W109906/06/2024Approval, on a advisory basis, the Company's executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1722920FOR172292FOR1 AXSOME THERAPEUTICS, INC.05464T104US05464T104306/07/2024To approve, by non-binding advisory vote, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER273480FOR27348FOR1 CALLIDITAS THERAPEUTICS ABW2R50Z137SE001044158406/17/2024APPROVE REMUNERATION REPORTSECTION 14A SAY-ON-PAY VOTESISSUER147000FOR14700FOR1 CARTESIAN THERAPEUTICS, INC.816212302US816212302506/14/2024To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation."SECTION 14A SAY-ON-PAY VOTESISSUER536860FOR53686FOR1 CHINOOK THERAPEUTICS, INC.16961L106US16961L106108/02/2023To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to Company's named executive officers in connection with the MergerSECTION 14A SAY-ON-PAY VOTESISSUER2474090FOR247409FOR1 CRINETICS PHARMACEUTICALS INC.22663K107US22663K107906/07/2024To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange CommissionSECTION 14A SAY-ON-PAY VOTESISSUER1151670FOR115167FOR1 GERON CORPORATION374163103US374163103605/09/2024To approve, on an advisory basis, the compensation of the company's named executive officers, as disclosed in the company's proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER8155480FOR815548FOR1 INSMED INCORPORATED457669307US457669307505/13/2024An advisory vote on the 2023 compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER1234940FOR123494FOR1 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/12/2024Approve, on a non-binding advisory basis, the compensation of the named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER187430FOR18743FOR1 IOVANCE BIOTHERAPEUTICS, INC.462260100US462260100706/11/2024To approve, by non-binding advisory vote, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER2666150FOR266615FOR1 IVERIC BIO, INC.46583P102US46583P102107/06/2023To approve, by non-binding, advisory vote, compensation that may be paid or become payable by IVERIC to its named executive officers in connection with the MergerSECTION 14A SAY-ON-PAY VOTESISSUER1689710FOR168971FOR1 KALVISTA PHARMACEUTICALS, INC.483497103US483497103209/26/2023Approve, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in this proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER1878270FOR187827FOR1 KARUNA THERAPEUTICS, INC.48576A100US48576A100703/12/2024To approve, on an advisory, non-binding basis, certain compensation that will or may be paid by Karuna to its named executive officers that is based on or otherwise related to the merger of Merger sub with and into Karuna pursuant to the merger agreement.SECTION 14A SAY-ON-PAY VOTESISSUER124580FOR12458FOR1 MADRIGAL PHARMACEUTICALS INC.558868105US558868105706/25/2024Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER133900FOR13390FOR1 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/05/2024Approval of, on an advisory basis, the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER709450FOR70945FOR1 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/05/2024Non-binding advisory vote on the frequency of future advisory votes on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER7094501 YEAR70945FOR1 MORPHIC HOLDING, INC.61775R105US61775R105906/04/2024To approve, on a non-binding advisory basis, the compensation paid to the Company's Named Executive OfficersSECTION 14A SAY-ON-PAY VOTESISSUER779620FOR77962FOR1 NATERA, INC.632307104US632307104206/12/2024To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER413170FOR41317FOR1 OLEMA PHARMACEUTICALS, INC.68062P106US68062P106606/13/2024Approval, on an advisory basis, of the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER1206080FOR120608FOR1 OSE IMMUNOTHERAPEUTICS SAF6913C100FR001212717306/19/2024APPROVAL OF FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS COMPRISING THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND PAID DURING THE CURRENT FINANCIAL YEAR OR AWARDED IN RESPECT OF THE PREVIOUS ONE, TO THE CHAIRMAN OF THE BOARD OF DIRECTORSSECTION 14A SAY-ON-PAY VOTESISSUER782660FOR78266FOR1 OSE IMMUNOTHERAPEUTICS SAF6913C100FR001212717306/19/2024APPROVAL OF FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS COMPRISING THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND PAID DURING THE CURRENT FINANCIAL YEAR OR AWARDED IN RESPECT OF THE PREVIOUS ONE, TO THE CHAIRMAN OF THE MANAGING DIRECTORSECTION 14A SAY-ON-PAY VOTESISSUER782660FOR78266FOR1 REATA PHARMACEUTICALS, INC.75615P103US75615P103009/21/2023To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Merger contemplated by the Merger AgreementSECTION 14A SAY-ON-PAY VOTESISSUER578410FOR57841FOR1 REGENXBIO INC.75901B107US75901B107005/31/2024To approve, on an advisory basis, the compensation paid to the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER124770FOR12477FOR1 REVOLUTION MEDICINES, INC.76155X100US76155X100006/20/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (''Say-on-Pay'')SECTION 14A SAY-ON-PAY VOTESISSUER250840FOR25084FOR1 SUTRO BIOPHARMA, INC.869367102US869367102106/06/2024To approve, on a non-binding, advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER4030140FOR403014FOR1 ULTRAGENYX PHARMACEUTICAL INC.90400D108US90400D108106/18/2024Advisory (non-binding) vote to approve the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER685060FOR68506FOR1 VIKING THERAPEUTICS INC92686J106US92686J106005/21/2024To approve, on an advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER354990FOR35499FOR1 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/17/2024To approve, on an advisory basis, the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER1116070FOR111607FOR1 XERIS BIOPHARMA HOLDINGS, INC.98422E103US98422E103806/05/2024To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER99844501 YEAR998445FOR1 XERIS BIOPHARMA HOLDINGS, INC.98422E103US98422E103806/05/2024To approve, on a non-binding advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER9984450FOR998445FOR1 ZENTALIS PHARMACEUTICALS, INC.98943L107US98943L107006/21/2024To approve, on an advisory (non-binding) basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER1461210FOR146121FOR1 ALX ONCOLOGY HOLDINGS INC00166B105US00166B105206/12/2024Advisory vote to approve named executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER5082120FOR508212FOR1 GERON CORPORATION374163103US374163103605/09/2024To approve, on an advisory basis, the compensation of the company's named executive officers, as disclosed in the company's proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER72276930FOR7227693FOR1 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/12/2024Approve, on a non-binding advisory basis, the compensation of the named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER3558320FOR355832FOR1 IOVANCE BIOTHERAPEUTICS, INC.462260100US462260100706/11/2024To approve, by non-binding advisory vote, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER10701020FOR1070102FOR1 IVERIC BIO, INC.46583P102US46583P102107/06/2023To approve, by non-binding, advisory vote, compensation that may be paid or become payable by IVERIC to its named executive officers in connection with the MergerSECTION 14A SAY-ON-PAY VOTESISSUER5500000FOR550000FOR1 OLEMA PHARMACEUTICALS, INC.68062P106US68062P106606/13/2024Approval, on an advisory basis, of the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER14495110FOR1449511FOR1 REGENXBIO INC.75901B107US75901B107005/31/2024To approve, on an advisory basis, the compensation paid to the Company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER4990780FOR499078FOR1 RELAY THERAPEUTICS, INC.75943R102US75943R102306/03/2024To consider and act upon an advisory vote on the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER8320170FOR832017FOR1 REVOLUTION MEDICINES, INC.76155X100US76155X100006/20/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (''Say-on-Pay'')SECTION 14A SAY-ON-PAY VOTESISSUER1666660FOR166666FOR1 SUTRO BIOPHARMA, INC.869367102US869367102106/06/2024To approve, on a non-binding, advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER24160730FOR2416073FOR1 VERVE THERAPEUTICS, INC.92539P101US92539P101206/06/2024Approval, on an advisory basis, of the compensation paid to our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER6381630FOR638163FOR1 VERVE THERAPEUTICS, INC.92539P101US92539P101206/06/2024Approval, on an advisory basis, of the frequency of future advisory votes on the compensation paid to our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER63816301 YEAR638163FOR1 ZENTALIS PHARMACEUTICALS, INC.98943L107US98943L107006/21/2024To approve, on an advisory (non-binding) basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER9083610FOR908361FOR1 ADAPTIMMUNE THERAPEUTICS PLC00653A107US00653A107905/14/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2023SECTION 14A SAY-ON-PAY VOTESISSUER40881120FOR4088112FOR1 ADAPTIMMUNE THERAPEUTICS PLC00653A107US00653A107905/14/2024To receive and approve our U.K. statutory directors' remuneration report for the year ended December 31, 2023 (excluding the directors' remuneration policy)SECTION 14A SAY-ON-PAY VOTESISSUER40881120FOR4088112FOR1 REPARE THERAPEUTICS INC.760273102US760273102506/17/2024To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER13898490FOR1389849FOR1